Trying to practice what I preach and finding time to exercise at #cmsc2023 between sessions ๐๐ช physical exercise has so many benefits for people with (and without!) MS ๐งก
#CMSC2023 Dr. Jennifer Graves (UC San Diego) Exercise and physical activity are key to managing people aging with MS โ โone of the best fountains of youth that we have.โ
Learn more about exercise and Physical Activity Recommendations for people with MS: https://t.co/3sZyDJECDW.
We're excited for 1st yr neuroimmunology-neurological infectious disease fellow, Dr. Samantha Roman (@SamRomanMD) who's presenting 2 posters at #AANAM: 1st is tomorrow (4/23) about Stiff Person Syndrome (# 5-021) & 2nd on 4/26 about autoimmune encephalitis (#3-005)
What a fantastic week of learning and networking at my first ACTRIMS Forum & Advanced Curriculum. Itโs an added bonus when you get to work and travel with friends (and make new ones) ๐ค
@drmystimd @ShuvroRoy @alexsimpsonmd@EmilySchorrMD@drgillyweed@SachinGadani @agfilippatou
#ACTRIMSForum 2023 is a wrap! This year's "MS: Going Viral" theme attracted record-breaking attendees, residents, abstract submissions and industry support. A huge thank you to our 1800+ registrants and speakers!
Amazing work by Thomas Garton from Johns Hopkins, bringing together lymphocyte, microglia, astrocyte pathology and synaptic pruning in the optic nerve at #ACTRIMS#ACTRIMS2023#C3
#ACTRIMSForum Dr. Tiffany Braley (U Michigan): cognitive behavioral therapy via telephone, modafinil, and combo of both all lessened MS fatigue in study funded by PCORI and National MS Society.
๐https://t.co/H8VNtU4hNY
So much excellent learning this week at #ACTRIMSForum and the preceding Advanced Curriculum. One of the most shocking things I learned this week was that neuroimmunology may bring in as much revenue for a hospital as neurosurgery! ๐คฏ
Dr. Dimitrios Ladakis presenting a poster on macrophage migration inhibitory factor (MIF) as a possible predictor of brain atrophy in people with primary progressive MS.
#ACTRIMS2023#HopkinsMSCenter
Dr. Bou Rjeily presenting data on clinical and radiological disease activity for patients on standard and extended interval dosing with ocrelizumab.
#ACTRIMS2023#WomenInNeurology#HopkinsMSCenter
Dr. Schorr discussing how serum GFAP may represent a biomarker of cord atrophy and progression, as levels correlate with decreased spinal cord volume in patients with primary progressive MS.
@EmilySchorrMD#ACTRIMS2023#WomenInNeurology#HopkinsMSCenter